News - Page 111 - Psychedelic Alpha

Our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts are now available.

Read more about the article PsyBio Therapeutics Initiates Commercial Biosynthetic Based Process Development for Psycho-Targeted and Psychoactive Compounds

PsyBio Therapeutics Initiates Commercial Biosynthetic Based Process Development for Psycho-Targeted and Psychoactive Compounds

Post published:June 2, 2022
Post category:Press Release

Read more about the article Mindmed Announces Voting Results for Annual General and Special Meeting

Mindmed Announces Voting Results for Annual General and Special Meeting

Post published:June 1, 2022
Post category:Press Release

Read more about the article Psychedelic Bulletin #104 – Mydecine CEO Downplays Insider Activity; UC Davis Scores $2.7m to Study Non-hallucinogenic Psychedelics; Oregon Health Authority Adopts Rules

Psychedelic Bulletin #104 – Mydecine CEO Downplays Insider Activity; UC Davis Scores $2.7m to Study Non-hallucinogenic Psychedelics; Oregon Health Authority Adopts Rules

Post published:May 27, 2022
Post category:Psychedelic Bulletin

Read more about the article Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome

Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome

Post published:May 22, 2022
Post category:Press Release

Read more about the article COMPASS Pathways presents largest ever study of psilocybin therapy, at American Psychiatric Association annual meeting

COMPASS Pathways presents largest ever study of psilocybin therapy, at American Psychiatric Association annual meeting

Post published:May 22, 2022
Post category:Press Release

Read more about the article Psychedelic Bulletin #103 – MAPS Phase 3 Trial On Schedule; Australia’s National Science Agency Working on Psychedelics; Death Spiral Financings

Psychedelic Bulletin #103 – MAPS Phase 3 Trial On Schedule; Australia’s National Science Agency Working on Psychedelics; Death Spiral Financings

Post published:May 22, 2022
Post category:Psychedelic Bulletin

Read more about the article CB Therapeutics granted a new patent that will help further provide eco-conscious avenues for psychedelic research

CB Therapeutics granted a new patent that will help further provide eco-conscious avenues for psychedelic research

Post published:May 19, 2022
Post category:Press Release

Read more about the article GH Research Reports First Quarter 2022 Financial Results and Provides Business Updates

GH Research Reports First Quarter 2022 Financial Results and Provides Business Updates

Post published:May 18, 2022
Post category:Press Release

Read more about the article Psychedelic Bulletin #102 – Our Analysis of MindMed’s LSD for Anxiety Results; Mail-Order Ketamine May Come Under Scrutiny; Our Notes from PSYCH Symposium

Psychedelic Bulletin #102 – Our Analysis of MindMed’s LSD for Anxiety Results; Mail-Order Ketamine May Come Under Scrutiny; Our Notes from PSYCH Symposium

Post published:May 16, 2022
Post category:Psychedelic Bulletin

Read more about the article Universal Ibogaine Co-Founder Dr Alberto Sola to Present at upcoming Research to Reality Conference

Universal Ibogaine Co-Founder Dr Alberto Sola to Present at upcoming Research to Reality Conference

Post published:May 13, 2022
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond. Psy Alpha Ltd is a company registered in England and Wales (16989109).

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.